Masimo (NSDQ:MASI) announced second-quarter results today that beat The Street, raising its guidance for the rest of the year.
The Irvine, Calif.–based patient monitoring technology company reported profits of $44.9 million, or $0.79 per share, on sales of $229.7 million for the three months ended June 29, with net income up 2.4% and sales increasing 13.6% compared with Q2 2018.
Adjusted to exclude one-time items, earnings per share were $0.76, 3¢ ahead of The Street, where analysts were looking for sales of $222.46 million.
“In the first half of the year, we introduced six important products, including Radius PPG, our Halo ION, and a neonatal version of our O3 Cerebral Oximetry monitor, all of which should help fuel our momentum,” Masimo CEO Joe Kiani said in a news release.
Masimo said it expects to log adjusted EPS of $3.15 this year, up from prior guidance of $3.12, increasing its adjusted top-line outlook to $925 million, compared with $918 million previously.